Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Calliditas Therapeutics (CALT)
NASDAQ:CALT
RESEARCH TOOLSreports
Holding CALT?
Track your performance easily
CALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.25 - $42.10
Previous Close$39.99
Volume4.04K
Average Volume (3M)8.92K
Market Cap
$1.07B
Enterprise Value$995.11M
Total Cash (Recent Filing)kr973.73M
Total Debt (Recent Filing)kr27.09M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 11, 2024EPS Estimate
$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,836,035
10 Day Avg. Volume7,481
30 Day Avg. Volume8,916
Standard Deviation0.22
R-Squared0.15
Alpha0.00625
Financial Highlights & Ratios
Price to Book (P/B)3.20
Price to Sales (P/S)9.26
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Calliditas Therapeutics News
PremiumCompany Announcements
Calliditas Therapeutics Sets Delisting Process
PremiumCompany Announcements
Calliditas Therapeutics Sees Strong Sales Growth
PremiumCompany Announcements
Calliditas Therapeutics’ Share Capital and Votes Increase
PremiumCompany Announcements
Calliditas’ Setanaxib Shows Promise in PBC Trial
Bulls Say, Bears Say
Bulls Say
Acquisition ApprovalThe board of directors of Calliditas unanimously recommends the shareholders accept Asahi Kasei’s offer, and the top shareholders, who control 44.65% of shares, have already agreed to the offer.
Patent PortfolioCALT's patent portfolio was recently strengthened with the MOU patent listed in the Orange Book, expiring in 2043.
Product ApprovalCalliditas’ Tarpeyo is the first and only therapy to receive full FDA approval for the treatment of IgA nephropathy.
Bears Say
Analyst RatingThe rating on CALT is downgraded to Neutral from Buy, with a new price target of $39.
Sales ImpactTarpeyo’s 1Q24 net sales were negatively impacted by $4.7M due to a cyberattack on Change Healthcare.
Therapeutic BenefitThe company will only present the KM curves at a future medical meeting, leaving uncertainties about the therapeutic benefit.
---
Ownership Overview
0.00%
Insiders
0.02% Mutual Funds
2.73% Other Institutional Investors
97.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CALT FAQ
What was Calliditas Therapeutics’s price range in the past 12 months?
Calliditas Therapeutics lowest stock price was $15.25 and its highest was $42.10 in the past 12 months.
What is Calliditas Therapeutics’s market cap?
Currently, no data Available
When is Calliditas Therapeutics’s upcoming earnings report date?
Calliditas Therapeutics’s upcoming earnings report date is Nov 11, 2024 which is in 54 days.
How were Calliditas Therapeutics’s earnings last quarter?
Calliditas Therapeutics released its earnings results on Aug 13, 2024. The company reported -$0.168 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.06.
Is Calliditas Therapeutics overvalued?
According to Wall Street analysts Calliditas Therapeutics’s price is currently Overvalued.
Does Calliditas Therapeutics pay dividends?
Calliditas Therapeutics does not currently pay dividends.
What is Calliditas Therapeutics’s EPS estimate?
Calliditas Therapeutics’s EPS estimate is $0.15.
How many shares outstanding does Calliditas Therapeutics have?
Calliditas Therapeutics has 29,790,043 shares outstanding.
What happened to Calliditas Therapeutics’s price movement after its last earnings report?
Calliditas Therapeutics reported an EPS of -$0.168 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went up 0.153%.
Which hedge fund is a major shareholder of Calliditas Therapeutics?
Currently, no hedge funds are holding shares in CALT
---
Calliditas Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CALT Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.50%
12-Months-Change
Fundamentals
Return on Equity
-159.97%
Trailing 12-Months
Asset Growth
4.26%
Trailing 12-Months
Company Description
Calliditas Therapeutics
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
---
CALT Company Deck
---
CALT Earnings Call
Q2 2024
0:00 / 0:00
---
CALT Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---